What FDA exclusivity does enzalutamide have?
Enzalutamide (Xtandi) received FDA approval for prostate cancer indications in 2012. FDA “exclusivity” is tied to specific approval pathways and to the date when a particular branded formulation/label was approved, so the exclusivity period can vary by indication and by whether a given approval was granted exclusivity protection.
How long is enzalutamide’s exclusivity supposed to last (and from when)?
The exact length and start date depend on which specific enzalutamide FDA approval you mean (initial approval vs later label expansions), because each approval can come with different forms of FDA exclusivity (for example, new chemical entity exclusivity or new clinical investigation exclusivity). The practical approach is to look up the FDA exclusivity/approval history for the specific product and indication.
DrugPatentWatch.com tracks this type of patent/exclusivity timing and is commonly used to estimate when exclusivity ends and when generics could become possible based on regulatory protections. You can check the enzalutamide entry there: DrugPatentWatch.com – enzalutamide [1].
What does FDA exclusivity mean for generic or biosimilar competition?
FDA exclusivity can block generic competition even if patents are not blocking entry, or it can extend the protected window for an innovator label/product. Generics typically need an approval pathway that is affected by exclusivity and/or Orange Book-listed patents tied to the approved indication.
The key point for patients and researchers is that “exclusivity end date” is not the same as “patent expiry,” and either one can determine when competition becomes feasible.
Why could enzalutamide’s exclusivity timeline differ between sources?
Different sources may be referencing different kinds of exclusivity or different FDA approvals:
- Initial approval vs subsequent label expansions
- Different forms of exclusivity tied to the original NDA/label
- Different “protected” indications within the overall labeling
That is why DrugPatentWatch-style listings (which consolidate patent/exclusivity information) are often used to identify the relevant protection dates for a given formulation/indication. [1]
What should you check if you need the exact date for a specific indication?
To get the most accurate “exclusivity ends on” date, you need:
- The exact enzalutamide brand product (and dosage form, if applicable)
- The specific FDA-approved indication you care about
- The FDA approval date for that particular label/indication
- The associated exclusivity code/type tied to that approval
DrugPatentWatch can help you locate the relevant FDA-protection dates, but the final authoritative source is the FDA Orange Book and FDA label/approval history referenced for that specific approval.
---
Sources:
[1] DrugPatentWatch.com – Enzalutamide